New guideline supports tailored evaluation of central precocious puberty

New Endocrine Society recommendations emphasize observation before investigation in selected children

A new Endocrine Society Clinical Practice Guideline recommends a more selective approach to diagnostic testing and treatment for children with suspected central precocious puberty (CPP), particularly in children whose early pubertal signs are mild or slowly progressive.^1,2

Don’t miss out on hearing about our latest peer-reviewed articles, expert opinions, conference news, podcasts and more.

Register Register

The guideline, published online in The Journal of Clinical Endocrinology & Metabolism on June 13, 2026, was also presented at ENDO 2026, the Endocrine Society’s annual meeting.^1,2 It addresses the evaluation and management of CPP, including when to observe, when to test, when to image, and when to initiate gonadotropin-releasing hormone agonist (GnRHa) therapy.¹

CPP is caused by early activation of the hypothalamic–pituitary–gonadal axis. It is usually defined as pubertal development before age 8 years in girls and before age 9 years in boys.¹ Early puberty may affect adult height and can be associated with psychosocial concerns, making timely assessment important.^1,2 However, the guideline emphasizes that the clinical course varies between children, and that immediate investigation or treatment is not always required.¹

Observation before testing

One of the key recommendations is that some girls with early breast development may be monitored before diagnostic testing is started. For girls aged 7–8 years with thelarche, the guideline suggests periodic physical examination every 4–6 months, including assessment of growth velocity and Tanner stage, before initiating laboratory or radiologic evaluation.

The guideline also suggests a 4–6-month observation period for girls younger than age 7 years who present with initial Tanner B2 breast development. This is intended to help distinguish transient or slowly progressive pubertal changes from rapidly progressive CPP.

Immediate evaluation remains appropriate when there are signs of more advanced or rapidly progressive puberty, accelerated growth, or symptoms that may suggest central nervous system involvement.

Simpler first-line diagnostic testing

When testing is needed, the guideline suggests starting with basal luteinizing hormone (LH) measured using an ultrasensitive assay, rather than using GnRH or GnRHa stimulation testing as the initial diagnostic test in all children. The authors note that basal LH testing may be more feasible than stimulation testing when an appropriate ultrasensitive assay is available. However, stimulation testing may still be needed when clinical suspicion remains high despite a low basal LH result.

Imaging and genetic testing

The guideline advises against routine brain magnetic resonance imaging (MRI) in girls aged 6–8 years and boys aged 8–9 years with CPP who do not have central nervous system symptoms. Routine genetic testing is also not recommended for all children with CPP. However, the guideline states that genetic testing may be considered in familial CPP, using shared decision-making with the child’s family.

Treatment considerations

GnRHa therapy remains an important treatment option for many children with CPP, but the guideline highlights that the expected benefit is not the same for every child. Children with slowly progressive puberty, or those who are already close to the later stages of pubertal growth, may have less to gain from treatment. For children who are expected to need long-term treatment, the guideline suggests starting with a longer-acting GnRHa preparation rather than beginning with monthly treatment and switching later. The guideline also recommends against routinely adding growth hormone to GnRHa therapy unless there is another established indication for growth hormone treatment.

Monitoring and discontinuation

During treatment, monitoring should primarily be based on clinical assessment, including growth, pubertal staging, and bone age. Routine biochemical monitoring of LH or sex steroid concentrations is not recommended unless there are clinical concerns that pubertal suppression is inadequate. The guideline also suggests that GnRHa therapy should not routinely continue beyond chronological age 10–11 years in girls or 11–12 years in boys, or beyond bone age 11–12 years in girls and 12–13 years in boys.

Clinical implications

The guideline supports a pragmatic approach to CPP, helping clinicians avoid unnecessary testing while still identifying children who need prompt evaluation or treatment. In practice, this means decisions should be guided by age, pubertal stage, rate of progression, growth pattern, neurologic symptoms, family history, and family preferences.

By distinguishing children who can be safely observed from those who may benefit from further investigation or treatment, the recommendations aim to support more proportionate and individualized care.

References

1. Latronico AC, Roberts SA, Alonzo M, et al. Central precocious puberty: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2026;dgag168.
2. Endocrine Society. Not all children with early puberty need the same level of testing or treatment. June 13, 2026. Available at: www.endocrine.org/news-and-advocacy/news-room/2026/not-all-children-with-early-puberty-need-the-same-level-of-testing-or-treatment (accessed June 26, 2026)